High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: Targeted plasma levels are achievable clinically

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 6, 1998, Pages 504-508

  Lara, Primo N ^a   Gandara, David R ^a   Wurz, Gregory T ^a   Lau, Derick ^a   Uhrich, Margaret ^a   Turrell, Corinne ^a   Raschko, James ^d   Edelman, Martin J ^c   Synold, Timothy ^d   Doroshow, James ^d   Muggia, Franco ^b   Perez, Edith A ^e   DeGregorio, Mike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Cisplatin; Lung cancer; Phase II trial; Protein kinase C; Toremifene

Indexed keywords

CISPLATIN; DRUG METABOLITE; PROTEIN KINASE; TOREMIFENE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 15444344801     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050852     Document Type: Article

References (17)

1. De Gregorio M, Ford J, Benz C, Wiebe V (1989) Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7 (9): 1359-1364
2. Eastman A, Schulte N, Sheibani N, Sorenson C (1988) Mechanisms of resistance to platinum drugs. In: Nicolini M (ed.) Platinum and other metal compounds in cancer chemotherapy. Nijhoff, Boston, pp 178-179
3. Fabian C, Sternson L, Barnett M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 64: 765-773
4. Gershanovich M, Moiseyenko V, Vorobjev A, et al (1997) High dose toremifene in advanced renal cell carcinoma. Cancer Chemother Pharmacol 39: 547-551
5. Haves D, Van Zyl JAm Hacking A, et al (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13(10): 2556-2566
6. Hoffman J, Doppler W, Jakob A, et al (1988) Enhancement of the antiproliferative effect of cisdiaminochloroplatinum and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 429: 382-388
7. Holleran W, Gharbo S, De Gregorio M (1987) Quantitation of toremifene and its major metabolites in human plasma by high-performance liquid chromatography following fluorescent activation. Anal Letters 20(6): 871-879
8. Liipo K, Ellmen J, Venttinen E, Anttila M (1997) Toremifene concentration and multidrug resistance in lung tumors. Cancer Chemother Pharmacol 39: 212-216
9. Maenpaa J, Sipila P, Kangas L, et al (1992). Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 46: 292-297
10. McClay E, Albright K, Jones E, et al (1992) Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52: 6790-6796
11. O'Brian C, Liskamp R, Solomon D, et al (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465
12. O'Brian C, Liskamp R, Solomon D, et al (1986). Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 76: 1243-1246
13. Perez EA, Poitras M, Gandara DR (1991) Evaluation of in vitro cytotoxicity of cisplatin plus toremifene in human non small cell lung cancer cell lines. Proc Am Assoc Cancer Res 32: 434
14. Perez EA, Gandara D, Webber L, et al (1994) High dose tamoxifen in combination with cisplatin: phase I trial and pharmacokinetic analysis. Proc Am Assoc Cancer Res 35: 246
15. Salomaa E, Liipo K, Ellmen J, Komi J (1996) Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer. Lung Cancer 16: 75-80
16. Wurz G, Emshoff V, De Gregorio M, Wiebe V (1993) Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother Pharmacol 31: 412-414
17. Wurz G, Soe L, Cadman T, DeGregorio M (1998) Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. Cancer Chemother Pharmacol (in press)